시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
면역관문억제제 시장 규모, 점유율, 성장 분석 : 유형별, 용도별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Immune Checkpoint Inhibitors Market Size, Share, and Growth Analysis, By Type (PD-1 Inhibitors, PD-L1 Inhibitors), By Application (Lung Cancer, Breast Cancer), By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드 : 1666044
리서치사 : SkyQuest
발행일 : 2025년 02월
페이지 정보 : 영문 189 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,657,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 8,957,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,258,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

면역관문억제제 세계 시장 규모는 2023년 484억 7,000만 달러로 평가되며, 2024년 568억 1,000만 달러에서 2032년 2,022억 2,000만 달러로 예측 기간(2025-2032년) 동안 17.2%의 CAGR로 성장할 것으로 예상됩니다.

흑색종, 호지킨 림프종과 함께 폐암, 유방암, 방광암, 자궁경부암 등 다양한 암의 발병률이 증가하면서 면역관문억제제의 채택이 증가하고 있습니다. 캐나다 암협회에 따르면, 캐나다인의 약 40%가 일생 동안 암 진단을 받고 사망 위험도 높기 때문에 효과적인 진단 및 치료 솔루션에 대한 수요가 증가하고 있습니다. 특히, 새로운 면역관문억제제 연구가 진행됨에 따라 시장이 확대되는 추세입니다. 특히, 유전자 종양 특성에 기반한 펨브롤리주맙의 FDA 승인은 표적 치료의 진보를 강조하고 있습니다. 기술 발전과 사회적 인식 개선 등 과제가 산적해 있지만, 면역관문억제제 시장은 특히 신흥국을 중심으로 강력한 성장 잠재력을 보여주며 이해관계자들에게 유망한 전망을 제시하고 있습니다.

목차

소개

조사 방법

주요 요약

시장 역학과 전망

주요 시장 인사이트

면역관문억제제 시장 규모 : 유형별

면역관문억제제 시장 규모 : 용도별

면역관문억제제 시장 규모 : 유통 채널별

면역관문억제제 시장 규모

경쟁 정보

주요 기업 개요

결론과 제안

ksm
영문 목차

영문목차

Global Immune Checkpoint Inhibitors Market size was valued at USD 48.47 billion in 2023 and is poised to grow from USD 56.81 billion in 2024 to USD 202.22 billion by 2032, growing at a CAGR of 17.2% during the forecast period (2025-2032).

The rising incidence of various cancers, including lung, breast, bladder, and cervical cancers, alongside melanomas and Hodgkin lymphoma, is driving the adoption of immune checkpoint inhibitors. According to the Canadian Cancer Society, approximately 40% of Canadians will receive a cancer diagnosis in their lifetime, with a significant mortality risk, fueling the demand for effective diagnostic and therapeutic solutions. The market is set for expansion, particularly with ongoing research into novel immune checkpoint inhibitors. Notably, pembrolizumab's FDA approval, based on genetic tumor features, highlights progress in targeted treatments. While challenges persist, including technological advancements and increased public awareness, the immune checkpoint inhibitors market demonstrates robust growth potential, especially in emerging economies, indicating a promising outlook for stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immune Checkpoint Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immune Checkpoint Inhibitors Market Segments Analysis

Global Immune Checkpoint Inhibitors Market is segmented by Type, Application, Distribution Channel and region. Based on Type, the market is segmented into PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors and Others. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Melanoma, Bladder Cancer, Hodgkin Lymphoma and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Immune Checkpoint Inhibitors Market

The global immune checkpoint inhibitors market has experienced substantial growth driven by technological innovations and scientific advancements in the field of immunotherapy. In recent years, extensive research has highlighted the essential function of the immune system in fighting cancer, resulting in the creation of therapies that bolster the body's natural immune response to neoplastic cells. As a result, immune checkpoint inhibitors have become a fundamental component of contemporary cancer treatment, specifically targeting and modulating proteins that control immune checkpoints. This evolution in cancer therapy is revolutionizing patient outcomes and expanding the potential for novel treatment options across various malignancies.

Restraints in the Global Immune Checkpoint Inhibitors Market

A major constraint impacting the global immune checkpoint inhibitors market is the steep cost of these therapies. Treatments like pembrolizumab (Keytruda) and nivolumab (Opdivo) carry high price tags due to the extensive investment in research and development, intricate manufacturing methods, and the exorbitant expenses associated with clinical trials. Consequently, a single treatment regimen can amount to tens of thousands of dollars, rendering it unaffordable for numerous patients and healthcare systems, particularly in low- and middle-income nations. This financial burden significantly hampers accessibility to these potentially life-saving therapies for a large segment of the population.

Market Trends of the Global Immune Checkpoint Inhibitors Market

The global immune checkpoint inhibitors market is witnessing significant growth, primarily driven by the rising incidence of cancer, which remains a major health challenge worldwide. As cancer rates continue to surge due to factors such as aging populations and lifestyle changes, the demand for innovative therapies is escalating. Immune checkpoint inhibitors, which have shown promising results in enhancing the immune response against tumors, are becoming essential in oncology treatment regimens. This upward trend is further fueled by ongoing research, the development of novel therapies, and expanding applications in various cancer types, positioning the market for robust expansion in the coming years.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Immune Checkpoint Inhibitors Market Size by Type & CAGR (2025-2032)

Global Immune Checkpoint Inhibitors Market Size by Application & CAGR (2025-2032)

Global Immune Checkpoint Inhibitors Market Size by Distribution Channel & CAGR (2025-2032)

Global Immune Checkpoint Inhibitors Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기